Human Apolipoprotein-H (β2Glycoprotein I) Matched Antibody Pair

Name: Human Apolipoprotein-H (β2Glycoprotein I) Matched Antibody Pair
SKU: ABPR-L030
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Plasma

Species Reactivity

Human

Detection Method

Sandwich ELISA

Intended Use

This antibody pair set comes with matched antibody pair to detect and quantify protein level of Human APOH

Contents of Kit

1. Capture Antibody (yellow): 0.5 ml of polyclonal affinity-purified anti-β2 GPI antibody for coating plates.
2. Detecting Antibody (red): 0.5 ml of peroxidase-conjugated polyclonal anti-β2 GPI antibody for detection of captured β2GPI.
Note: Reagents are sufficient for at least 5×96 well plates using recommended protocols. Antibodies are supplied in a 50% (v/v) glycerol solution for storage at –10 to -20°C. Keep vials tightly capped. Do not store in frost-free freezers.

Storage

-10 to -20°C

General Description

Apolipoprotein-H, also known as β2-Glycoprotein I (β2GPI), is a plasma glycoprotein that circulates at a concentration of 200 ug/ml (4 μM). Synthesized in the liver, β2GPI is a single chain molecule of 48 kDa, consisting of five repeating internally disulphide-bonded structures referred to as sushi domains. Relative to other glycoproteins, β2GPI has an unusually high content of cysteine (6.2%), proline (8.3%) and carbohydrate (19%). Almost half the circulating β2GPI in plasma is associated with lipoproteins of all major fractions. β2GPI has been demonstrated to bind negatively charged phospholipids, heparin and platelets. Although the precise function(s) are as yet unknown, β2GPI has been demonstrated to interfere with blood coagulation by competitively binding to negatively charged phospholipid surfaces exposed during cell activation or damage. Recent evidence also implicates β2GPI as a cofactor recognized by anti-phospholipid antibodies present in some autoimmune disorders such as systemic lupus erythematosus (SLE).

Citations

Have you cited ABPR-L030 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Genetic polymorphisms of apolipoproteins A-IV, E and H in Koreans

HUMAN HEREDITY

Authors: Kim, HS; Kamboh, MI

Abstract

A South Korean population from Kongju (n = 350) was screened by isoelectric focusing and immunoblotting procedures to determine the distribution of genetic variations in 3 apolipoprotein genes including APOA-TV, APOE and APOH. Although the known APOA-IV protein polymorphism was not observed, sporadic examples of 2 putative new variants were identified. The frequencies of the APOE*2, APOE*3 and APOE*4 alleles were 0.069, 0.823 and 0.107, respectively. At the APOH structural locus 3 common alleles, APOH*1 (0.010), APOH*2 (0.913) and APOH*3 (0.073) were observed. In addition, a unique APOH allele designated APOH*3 Kongju was identified in this Korean population.

Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy

LIVER INTERNATIONAL

Authors: Sultanik, Philippe; Mallet, Vincent; Lagaye, Sylvie; Casrouge, Armanda; Dorival, Celine; Barthe, Yoann; Fontaine, Helene; Hezode, Christophe; Mottez, Estelle; Bronowicki, Jean-Pierre; Carrat, Fabrice; Theodorou, Ioannis; Abel, Laurent; Gayat, Etienne; Fontanet, Arnaud; Pol, Stanislas; Albert, Matthew L.

Abstract

Background & AimsChronic infection with HCV remains a public health problem with approximately 150 million people infected worldwide. HCV intersects with lipid metabolism for replication and entry; and plasma concentrations of apolipoproteins have been identified as predictors for response to therapy. Herein, we conducted a screen of plasma proteins, including all apolipoproteins, to identify correlates of response to pegylated-interferon/ribavirin (PR) and HCV non-structural protein 3 (NS3) inhibitors (i.e., telaprevir/boceprevir) therapy in treatment-experienced cirrhotic patients from the ANRS CUPIC cohort. MethodsWe analysed 220 baseline plasma protein concentrations in 189 patients using Luminex technology and analyzed results. ResultsWe identified baseline levels of apolipoprotein H (apoH) as a surrogate marker for sustained virological response (SVR). Notably, increased plasma concentration of apoH, used in combination with known clinical parameters, established a robust model with improved classification of patients as likely to achieve SVR (AUC=0.77, Se=66%, Sp=72%, NRI=39%). Moreover, we provide mechanistic information that indicates a previously unidentified role for apoH during viral entry. Using a human liver slices HCV infection model, we demonstrate that apoH limits replication. ConclusionThese data support testing of new biomarker strategies for the management of cirrhotic HCV patients and expand our understanding of how apoH may intersect with HCV infection.